328 related articles for article (PubMed ID: 26315534)
1. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
Corrales L; Gajewski TF
Cytokine; 2016 Jan; 77():245-7. PubMed ID: 26315534
[No Abstract] [Full Text] [Related]
2. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
3. Insight into the dichotomous regulation of STING activation in immunotherapy.
Hu Z; Yang Y; Fang L; Zhou J; Zhang H
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
[TBL] [Abstract][Full Text] [Related]
4. STING signaling: a key to therapeutic tumor immunity.
Foote JB; Emens LA
Immunotherapy; 2018 Jul; 10(9):729-731. PubMed ID: 30008260
[No Abstract] [Full Text] [Related]
5. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity.
Leventhal DS; Sokolovska A; Li N; Plescia C; Kolodziej SA; Gallant CW; Christmas R; Gao JR; James MJ; Abin-Fuentes A; Momin M; Bergeron C; Fisher A; Miller PF; West KA; Lora JM
Nat Commun; 2020 Jun; 11(1):2739. PubMed ID: 32483165
[TBL] [Abstract][Full Text] [Related]
6. Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies.
Huang M; Cha Z; Liu R; Lin M; Gafoor NA; Kong T; Ge F; Chen W
Front Immunol; 2024; 15():1399926. PubMed ID: 38817608
[TBL] [Abstract][Full Text] [Related]
7. Interferon-Independent Activities of Mammalian STING Mediate Antiviral Response and Tumor Immune Evasion.
Wu J; Dobbs N; Yang K; Yan N
Immunity; 2020 Jul; 53(1):115-126.e5. PubMed ID: 32640258
[TBL] [Abstract][Full Text] [Related]
8. Oncology meets immunology: the cancer-immunity cycle.
Chen DS; Mellman I
Immunity; 2013 Jul; 39(1):1-10. PubMed ID: 23890059
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract][Full Text] [Related]
10. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
[TBL] [Abstract][Full Text] [Related]
11. The host STING pathway at the interface of cancer and immunity.
Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
[TBL] [Abstract][Full Text] [Related]
12. Histamine in cancer immunology and immunotherapy. Current status and new perspectives.
Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA
Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067
[TBL] [Abstract][Full Text] [Related]
13. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.
Ye Y; Xu C; Chen F; Liu Q; Cheng N
Front Immunol; 2021; 12():771201. PubMed ID: 34899721
[TBL] [Abstract][Full Text] [Related]
14. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
15. Is cancer vaccination feasible at older age?
Gravekamp C; Jahangir A
Exp Gerontol; 2014 Jun; 54():138-44. PubMed ID: 24509231
[TBL] [Abstract][Full Text] [Related]
16. Basic concepts in glioma immunology.
Parney IF
Adv Exp Med Biol; 2012; 746():42-52. PubMed ID: 22639158
[TBL] [Abstract][Full Text] [Related]
17. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
18. The cGAS-STING Pathway: A Promising Immunotherapy Target.
Ou L; Zhang A; Cheng Y; Chen Y
Front Immunol; 2021; 12():795048. PubMed ID: 34956229
[TBL] [Abstract][Full Text] [Related]
19. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
[TBL] [Abstract][Full Text] [Related]
20. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
